NEWSSHIFTBIO's SIRP-EV achieved an Orphan Drug Designation(ODD) for Acute Liver Failure from FDA

27 Jan 2024

We are delighted to announce our first achievement in 2024.
As of yesterday (01/25/24), SIRP-EV achieved an Orphan Drug Designation (ODD) for acute liver failure (severe acute liver injury) from the US FDA. This designation is a significant milestone for us, affirming ALI's high unmet medical needs and the US FDA's acknowledgment of SIRP-EV's potential as a therapeutic solution.

At SHIFTBIO, we are dedicated to advancing innovative drug development based on our ESM platform, striving to persistently offer new opportunities to patients.